PD L1 News and Research

RSS

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Outcomes for patients with clear cell renal cell carcinoma have improved over the past decade due to the approval of immunotherapies, yet still there is a subset of patients who do not respond to this type of therapy.

26 Apr 2023

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.

25 Apr 2023

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

17 Apr 2023

Diverse subset of T-cell clones plays a role in the antitumor effects of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are widely sought after for the treatment of different types of cancers. Unfortunately, only 20–30% patients with cancer respond to ICI treatment.

29 Mar 2023

Newly found strategy used by metastasized tumors may explain why some promising immunotherapies fail

Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.

28 Mar 2023

Advancements in understanding and treating breast cancer

Researchers describe recent advancements in breast cancer research.

26 Mar 2023

Leaving lymph nodes intact until after immunotherapy could boost efficacy against solid tumors

Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells.

20 Mar 2023

Ferroptosis could be the key to making effective immunotherapies against liver cancer

Iron-dependent cell death (ferroptosis) is a type of programmed cell death by means of which the body kills off diseased, defective or superfluous cells.

17 Feb 2023

Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

15 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

New therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line

A new research perspective was published in Genes & Cancer on January 30, 2023, entitled, "Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines."

3 Feb 2023

Researchers develop AI-based strategy for discovering high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

30 Jan 2023

Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

A combination of chemotherapy and drugs that stimulate the immune system to combat cancer is increasingly used to control progression of the disease in patients.

30 Jan 2023

New therapy-relevant marker may help identify ER+ breast cancer patients who may benefit from immunotherapies

A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.

26 Jan 2023

PD L1 News and Research

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Diverse subset of T-cell clones plays a role in the antitumor effects of immune checkpoint inhibitors

Newly found strategy used by metastasized tumors may explain why some promising immunotherapies fail

Advancements in understanding and treating breast cancer

Leaving lymph nodes intact until after immunotherapy could boost efficacy against solid tumors

Ferroptosis could be the key to making effective immunotherapies against liver cancer

Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

New therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line

Researchers develop AI-based strategy for discovering high-affinity antibody drugs

Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

New therapy-relevant marker may help identify ER+ breast cancer patients who may benefit from immunotherapies

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Extracellular vesicles enhance cancer immunotherapy

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News